The Outbreak Escalates

Since our last coverage, three developments have shifted the situation significantly.

First, the World Health Organization formally declared the Bundibugyo Ebola outbreak a Public Health Emergency of International Concern (PHEIC) on May 17, 2026 — according to WHO.int. That's the highest alarm level short of a full pandemic designation.

Second, an American citizen tested positive for Ebola. According to the CDC, a U.S. national exposed while caring for patients in the DRC tested positive on May 17. The patient was evacuated to Germany — not the United States — for treatment, and is currently listed in stable condition. Germany has prior experience managing Ebola patients and offered a shorter flight time from the region.

Third, the virus jumped to Kampala, Uganda's capital city. Two laboratory-confirmed cases with no apparent link to each other were reported there on May 15 and 16, both involving individuals who had traveled from the DRC. That's a capital city with an international airport, not a rural containment problem.

The Numbers Are Official — And Growing

As of June 1, 2026, the CDC reports 321 confirmed cases and 48 confirmed deaths in the DRC, plus 11 confirmed cases and 1 confirmed death in Uganda, with 1 additional probable case and death in Uganda.

The Wall Street Journal has designated this the third largest Ebola outbreak in recorded history. It is only the third outbreak ever driven by the Bundibugyo strain specifically — and there are ZERO licensed vaccines or therapeutics that target it.

We have vaccines for the Zaire strain (Merck's Ervebo, J&J's Zabdeno/Mvabea). We have nothing approved for Bundibugyo. The people getting sick right now have no licensed medical intervention available to them.

The U.S. Government Responded

On May 18, CDC and DHS announced enhanced travel screening and entry restrictions. Travelers flying from DRC, South Sudan, and Uganda will be rerouted to land at one of four designated airports: Washington-Dulles (IAD), Atlanta Hartsfield-Jackson (ATL), George Bush Intercontinental (IAH), or JFK.

South Sudan has reported ZERO cases, but it borders the affected countries and is included anyway.

The CDC is clear: no Ebola cases from this outbreak have been confirmed inside the United States. The risk to the general American public remains low.

Moderna, Oxford, and the Race for a Vaccine

CEPI committed $61.8 million across three vaccine candidates, as previously reported.

Moderna gets $50 million — the largest slice — for preclinical development and Phase 1 clinical trials of its mRNA-based Bundibugyo vaccine candidate, according to Ars Technica. Moderna CEO Stéphane Bancel said the company will "move with urgency and scientific rigor."

The University of Oxford and Serum Institute of India get $8.6 million for preclinical work using an adenovirus-based platform — the same approach used for their COVID-19 vaccine. The International AIDS Vaccine Initiative gets $3.2 million for a candidate using the rVSV platform, the same technology behind Merck's approved Zaire Ebola vaccine.

WHO Director-General Dr. Tedros Adhanom Ghebreyesus called this "exactly the kind of cross-sectoral collaboration that epidemic response demands." CEPI CEO Dr. Richard Hatchett said, according to Euronews: "Every day counts in the race against this deadly disease."

None of these vaccines are close to approved. Phase 1 trials haven't started. In a best-case scenario, these candidates are 12-18 months from any emergency authorization.

The Detection Problem

The outbreak's detection was delayed, as Ars Technica noted. The virus was spreading before officials knew what they were dealing with. That delay, combined with active armed conflict in the DRC's Ituri Province and high population mobility, accelerated case growth. This isn't a failure of vaccines. It's a failure of early detection infrastructure.

The U.S. government moved with travel restrictions the day after the American case was confirmed.

What This Means Now

If you're an average American not traveling to DRC, Uganda, or South Sudan, your personal risk is genuinely low.

But an American health worker is infected. The virus is in Kampala. The WHO has sounded its highest alarm. And there is no approved treatment for this specific strain.

The outbreak is being addressed with vaccine commitments that won't produce results for over a year while transmission continues. The funding is substantial. The urgency is real. The timeline is sobering.